SMARCA4 deficient Uterine sarcoma is a rare but highly aggressive sarcoma.
Diagnostic dilemma is the major hurdle.
Germline testing warranted to identify hereditary syndrome (RTPS).
Established chemotherapeutic guidelines for SDUS is sparse.
Gemcitabine-taxol based regimen yielded significant clinic-radiological benefit.